Medication info
Duo Telmisartan 80/5 mg

Duo Telmisartan 80/5 mg

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›80mg / 1 tabletRosuvastatin Calcium›5.2mg / 1 tablet
Manufacturer / importer
HuTecs Pharmaceutical Co., Ltd.
Appearance
Bright pink oval film-coated tablet
Packaging
30 tablets/box [10 tablets/PTP×3]
Approval status
Active

MFDS item code 202005517 · Approved 2020.07.29 · Insurance code 649105010

Summary

Main use
Treatment of hypertension, improvement of dyslipidemia, and inhibition of cardiovascular disease risk and progression of arteriosclerosis
Who takes it
Adults
Adult dose
This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan and rosuvastatin components. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg of telmisartan taken orally once daily; for some patients, 20 mg once daily may be effective. If necessary, the dose may be increased to 80 mg once daily. When this medicine is coadministered with a thiazide diuretic such as hydrochlorothiazide, it has an additional blood pressure-lowering effect. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after treatment is started. 2. Reduction of cardiovascular risk Adults: The recommended dose is 80 mg of this medicine taken orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When starting treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive medication may be required. 3. Patients with hepatic impairment Administer with caution to patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to the LDL cholesterol level, treatment goal, and patient response, and may be increased to a maximum of 20 milligrams daily. 2. Older adults: No dosage adjustment is necessary. 3. Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.

Ingredients

Manufacturer
HuTecs Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension, improvement of dyslipidemia, and inhibition of cardiovascular disease risk and progression of arteriosclerosis

  • Essential hypertension
  • coronary artery disease
  • peripheral artery disease
  • stroke
  • transient ischemic attack
  • clinical evidence of damage to peripheral organs
  • high-risk diabetes
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • combined hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
View approved original text

This medication is used for patients who need to take telmisartan and rosuvastatin together. Telmisartan is used for the treatment of hypertension and plays a role in reducing the risk of cardiovascular diseases, such as myocardial infarction or stroke. It particularly reduces the risk of death from cardiovascular diseases in high-risk patients. Rosuvastatin improves lipid abnormalities such as hypercholesterolemia, slows the progression of atherosclerosis, and reduces the risk of cardiovascular diseases. Additionally, it is used as an adjunct to diet in certain patients with familial hypercholesterolemia. This combination effectively helps improve cardiovascular health.

How to take

Adult dose

This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan and rosuvastatin components. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg of telmisartan taken orally once daily; for some patients, 20 mg once daily may be effective. If necessary, the dose may be increased to 80 mg once daily. When this medicine is coadministered with a thiazide diuretic such as hydrochlorothiazide, it has an additional blood pressure-lowering effect. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after treatment is started. 2. Reduction of cardiovascular risk Adults: The recommended dose is 80 mg of this medicine taken orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When starting treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive medication may be required. 3. Patients with hepatic impairment Administer with caution to patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to the LDL cholesterol level, treatment goal, and patient response, and may be increased to a maximum of 20 milligrams daily. 2. Older adults: No dosage adjustment is necessary. 3. Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.

Precautions

This medication can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters, so it must be discontinued immediately if pregnancy is confirmed. People who are allergic to this drug or its components, pregnant women or women of childbearing potential, and nursing mothers should not take it. Patients with severely impaired liver function or issues with bile excretion, patients with severely reduced kidney function, and patients with muscle diseases or a history of angioedema should also avoid this medication. Elderly patients, patients with high potassium levels, and patients with mildly impaired liver function must use this medication cautiously, and liver function tests and muscle condition should be monitored regularly. This medication can cause serious side effects such as myalgia or muscle weakness, and in severe cases, rhabdomyolysis involving muscle tissue destruction, so if muscle pain or weakness occurs, consult a doctor immediately. This medication can also affect liver function, so if liver enzyme levels are elevated, discontinue use and follow medical advice. There may be interactions with other medications, so it is essential to inform the doctor or pharmacist about any other medications being taken, especially when combined with potassium-sparing diuretics, lithium, diuretics, and non-steroidal anti-inflammatory drugs, as blood pressure, kidney function, and electrolyte levels need to be monitored frequently. This medication may cause dizziness or drowsiness when driving or operating machinery, so caution is advised. Keep out of reach of children and do not transfer to another container.

Side effects

Headache, orthostatic dizziness, somnolence, increase in blood pressure, decrease in blood pressure, hypotension, elevated ALT, dysuria, rhinitis, pharyngeal discomfort, pulmonary disease, unspecified gastrointestinal disease, benign gastrointestinal neoplasm, hemorrhoids, skeletal pain, osteoporosis, sensory impairment, movement disorders, atherosclerosis, frequent urination, tinnitus, hearing loss, halitosis, fatty liver, upper respiratory infection, urinary tract infection, sepsis, anemia, thrombocytopenia, eosinophilia, hypersensitivity, anaphylactic reaction, hyperkalemia, hypoglycemia, depression, insomnia, anxiety, syncope, visual disturbances, dizziness, bradycardia, tachycardia, dyspnea, abdominal pain, diarrhea, dyspepsia, abdominal distension, vomiting, abdominal discomfort, dry mouth, liver dysfunction, liver disorder, increased sweating, itching, rash, erythema, vascular edema, drug rash, toxic skin eruption, eczema, urticaria, myalgia, lumbago, muscle cramps, arthralgia, limb pain, tendon pain, acute renal failure, chest pain, asthenia, influenza-like illness, elevated serum creatinine, elevated serum uric acid, increased liver enzymes, elevated serum CK, reduced hemoglobin, decreased libido, facial edema, alopecia, conjunctivitis, tinnitus, petechiae, polyneuropathy, memory loss, peripheral neuropathy, hyperventilation, pneumonia, cough, flushing, erectile dysfunction, loss of appetite, edema, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disturbances, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive decline, forgetfulness, amnesia, memory impairment, confusion, severe muscle weakness, ophthalmoplegic myasthenia, constipation, nausea, pancreatitis, itching, myopathy, rhabdomyolysis, asthenia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it should be stored in a tightly closed container. The recommended storage temperature is between 1 and 30 degrees Celsius at room temperature. Proper storage will help maintain the effectiveness and safety of the medication for a long time.

Appearance and packaging

Appearance

Bright pink oval film-coated tablet

Package unit

30 tablets/box [10 tablets/PTP×3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.